Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics·2016
Same author

Using Tomoauto: A Protocol for High-throughput Automated Cryo-electron Tomography.

Journal of visualized experiments : JoVE·2016
Same author

MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10.

Clinical immunology (Orlando, Fla.)·2016
Same author

Minicells, Back in Fashion.

Journal of bacteriology·2016
Same author

A new variant of rabbit hemorrhagic disease virus G2-like strain isolated in China.

Virus research·2016
Same author

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2016
Same journal

Shared frailty sieve estimation for dependent left truncated and interval censored data.

Lifetime data analysis·2026
Same journal

Functional win-fractions regression models for composite outcomes.

Lifetime data analysis·2026
Same journal

Variable selection in causal semiparametric transformation models with all-or-nothing treatment compliance.

Lifetime data analysis·2026
Same journal

Correction to: A uniformisation-driven algorithm for inference-related estimation of a phase-type ageing model.

Lifetime data analysis·2026
Same journal

Unobserved heterogeneity in threshold regression based on the hitting times of a reflected Brownian motion for recurrent hypoglycemia.

Lifetime data analysis·2026
Same journal

Variable selection with broken adaptive ridge regression for interval-censored competing risks data.

Lifetime data analysis·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Modeling potential time to event data with competing risks.

Liang Li1, Bo Hu, Michael W Kattan

  • 1Department of Quantitative Health Sciences, Cleveland Clinic, 9500 Euclid Ave., JJN3, Cleveland, OH, 44195, USA, lil2@ccf.org.

Lifetime Data Analysis
|September 25, 2013
PubMed
Summary
This summary is machine-generated.

This study introduces a statistical model to predict prostate cancer metastasis risk after surgery, considering death as a competing risk. It helps estimate outcomes without additional therapies for better clinical decisions.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 7, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

  • Oncology
  • Biostatistics
  • Epidemiology

Background:

  • Radical prostatectomy patients face risks of metastasis or prostate cancer death.
  • Adjuvant or salvage therapies are often needed but have side effects.
  • Accurate risk prediction is crucial for informed clinical decision-making.

Purpose of the Study:

  • To estimate the cumulative incidence of cancer metastasis after prostatectomy.
  • To account for competing risks, specifically death.
  • To predict metastasis risk under the hypothetical scenario of no additional therapy.

Main Methods:

  • Utilized the Fine and Gray competing risks model.
  • Adjusted for treatment choice using inverse probability censoring weighting (IPCW).
  • Applied double IPCW weights for model fitting in standard statistical software.

Main Results:

  • The methodology was applied to a prostate cancer cohort.
  • Predicted post-prostatectomy cumulative incidence of metastasis without further treatment.
  • Demonstrated a method to handle treatment choices in observational studies.

Conclusions:

  • The proposed statistical approach provides a robust method for predicting prostate cancer metastasis.
  • This model aids in clinical decision-making by estimating metastasis risk independent of adjuvant therapies.
  • The findings are valuable for managing patients post-prostatectomy, balancing treatment benefits and risks.